Conjugating Prussian blue nanoparticles onto antigen-specific T cells as a combined nanoimmunotherapy.
Nanomedicine (Lond)
; 11(14): 1759-67, 2016 07.
Article
em En
| MEDLINE
| ID: mdl-27389189
ABSTRACT
AIM:
To engineer a novel nanoimmunotherapy comprising Prussian blue nanoparticles (PBNPs) conjugated to antigen-specific cytotoxic T lymphocytes (CTL), which leverages PBNPs for their photothermal therapy (PTT) capabilities and Epstein-Barr virus (EBV) antigen-specific CTL for their ability to traffic to and destroy EBV antigen-expressing target cells. MATERIALS &METHODS:
PBNPs and CTL were independently biofunctionalized. Subsequently, PBNPs were conjugated onto CTL using avidin-biotin interactions. The resultant cell-nanoparticle construct (CTLPBNPs) were analyzed for their physical, phenotypic and functional properties.RESULTS:
Both PBNPs and CTL maintained their intrinsic physical, phenotypic and functional properties within the CTLPBNPs.CONCLUSION:
This study highlights the potential of our CTLPBNPs nanoimmunotherapy as a novel therapeutic for treating virus-associated malignancies such as EBV+ cancers.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfócitos T Citotóxicos
/
Herpesvirus Humano 4
/
Infecções por Vírus Epstein-Barr
/
Corantes
/
Nanopartículas
/
Ferrocianetos
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Nanomedicine (Lond)
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos